PMC:7278640
Annnotations
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 18-26 | SP_7 | denotes | COVID-19 |
T2 | 266-277 | NCBITaxon:11118 | denotes | Coronavirus |
T3 | 292-300 | SP_7 | denotes | COVID-19 |
T4 | 355-363 | SP_7 | denotes | COVID-19 |
T5 | 488-496 | SP_7 | denotes | COVID-19 |
T6 | 670-678 | SP_7 | denotes | COVID-19 |
T7 | 1285-1298 | CHEBI:52217;CHEBI:52217 | denotes | pharmacologic |
T8 | 1334-1345 | CHEBI:23888;CHEBI:23888 | denotes | medications |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1 | 18-26 | Disease | denotes | COVID-19 | MESH:C000657245 |
6 | 266-290 | Disease | denotes | Coronavirus disease 2019 | MESH:C000657245 |
7 | 292-300 | Disease | denotes | COVID-19 | MESH:C000657245 |
8 | 355-363 | Disease | denotes | COVID-19 | MESH:C000657245 |
9 | 670-678 | Disease | denotes | COVID-19 | MESH:C000657245 |
14 | 1127-1139 | Species | denotes | participants | Tax:9606 |
15 | 1209-1221 | Species | denotes | participants | Tax:9606 |
17 | 488-496 | Disease | denotes | COVID-19 | MESH:C000657245 |
59 | 670-678 | Disease | denotes | COVID-19 | MESH:C000657245 |
127 | 670-678 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 18-26 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T2 | 266-290 | Disease | denotes | Coronavirus disease 2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 292-300 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 355-363 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T5 | 488-496 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T6 | 670-678 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-1 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T2 | 105-106 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T3 | 148-149 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T4 | 390-400 | http://purl.obolibrary.org/obo/BFO_0000030 | denotes | Objectives |
T5 | 535-547 | http://purl.obolibrary.org/obo/OBI_0000245 | denotes | Organization |
T6 | 1193-1194 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T7 | 1456-1460 | http://purl.obolibrary.org/obo/CLO_0008416 | denotes | peer |
T8 | 1456-1460 | http://purl.obolibrary.org/obo/CLO_0050081 | denotes | peer |
T9 | 1526-1527 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-127 | Sentence | denotes | A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis |
T2 | 128-138 | Sentence | denotes | Background |
T3 | 139-311 | Sentence | denotes | There is a pressing need for evidence-based interventions to address the devastating clinical and public health effects of the Coronavirus disease 2019 (COVID-19) pandemic. |
T4 | 312-389 | Sentence | denotes | The number of registered trials related to COVID-19 is increasing by the day. |
T5 | 390-400 | Sentence | denotes | Objectives |
T6 | 401-497 | Sentence | denotes | To describe the characteristics of the currently registered clinical trials related to COVID-19. |
T7 | 498-505 | Sentence | denotes | Methods |
T8 | 506-628 | Sentence | denotes | We searched the World Health Organization (WHO)’s International Clinical Trials Registry Platform (ICTRP) on May 15, 2020. |
T9 | 629-679 | Sentence | denotes | We included any entry that is related to COVID-19. |
T10 | 680-901 | Sentence | denotes | We abstracted then descriptively analyzed the following characteristics of the registered trials: study design, status, phase, primary endpoints, experimental interventions, and geographic location among other qualifiers. |
T11 | 902-909 | Sentence | denotes | Results |
T12 | 910-957 | Sentence | denotes | We identified 1,308 eligible registered trials. |
T13 | 958-1112 | Sentence | denotes | The majority of trials were initially registered with ClinicalTrials.gov (n= 703; 53.7%) and the Chinese Clinical Trial Registry (ChiCTR) (n= 291; 22.2%). |
T14 | 1113-1232 | Sentence | denotes | The number of participants to be enrolled across these trials was 734,657, with a median of 110 participants per trial. |
T15 | 1233-1380 | Sentence | denotes | The most-commonly studied intervention category was pharmacologic (n=763; 58.3%), with antiparasitic medications being the most common subcategory. |
T16 | 1381-1505 | Sentence | denotes | While over half of trials were already recruiting, we identified published peer-reviewed results for only 8 of those trials. |
T17 | 1506-1516 | Sentence | denotes | Conclusion |
T18 | 1517-1611 | Sentence | denotes | There is a relatively large number of registered trials but very few results published so far. |
T19 | 1612-1807 | Sentence | denotes | While our findings suggest an appropriate initial response by the research community, the real challenge will be to get these trials completed, published, and translated into practice and policy. |